LAG-3 Expression Predicts Outcome in Stage II Colon Cancer
| العنوان: | LAG-3 Expression Predicts Outcome in Stage II Colon Cancer |
|---|---|
| المؤلفون: | José A. Galván, Richard Kirsch, Inti Zlobec, Martin D. Berger, Alessandro Lugli, Gaëlle Rhyner Agocs, Heather Dawson, Naziheh Assarzadegan |
| المصدر: | Journal of Personalized Medicine Volume 11 Issue 8 Rhyner Agocs, Gaëlle; Assarzadegan, Naziheh; Kirsch, Richard; Dawson, Heather; Galván, José A.; Lugli, Alessandro; Zlobec, Inti; Berger, Martin D. (2021). LAG-3 Expression Predicts Outcome in Stage II Colon Cancer. Journal of personalized medicine, 11(8) MDPI 10.3390/jpm11080749 <http://dx.doi.org/10.3390/jpm11080749Test> Journal of Personalized Medicine, Vol 11, Iss 749, p 749 (2021) |
| بيانات النشر: | MDPI, 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, Colorectal cancer, T cell, Medicine (miscellaneous), 610 Medicine & health, survival, Article, 03 medical and health sciences, 0302 clinical medicine, LAG-3, Internal medicine, Medicine, immune checkpoint, Tumor microenvironment, Tissue microarray, business.industry, medicine.disease, Immune checkpoint, Immunosurveillance, 030104 developmental biology, medicine.anatomical_structure, colon cancer, 030220 oncology & carcinogenesis, 570 Life sciences, biology, Biomarker (medicine), biomarker, Cytokine secretion, business |
| الوصف: | Introduction: LAG-3 is an inhibitory immune checkpoint molecule that suppresses T cell activation and inflammatory cytokine secretion. T cell density in the tumor microenvironment of colon cancer plays an important role in the host’s immunosurveillance. We therefore hypothesized that LAG-3 expression on tumor-infiltrating lymphocytes (TILs) predicts outcome in patients with stage II colon cancer. Patients and Methods: Immunohistochemical staining for LAG-3 was performed on tissue microarrays (TMAs) of formalin-fixed paraffin-embedded tissue from 142 stage II colon cancer patients. LAG-3 expression was assessed in TILs within both the tumor front and tumor center and scored as either positive or negative. The primary endpoint was disease-free survival (DFS). Results: In patients diagnosed with stage II colon cancer, the presence of LAG-3 expression on TILs was significantly associated with better 5-year DFS (HR 0.34, 95% CI 0.14–0.80, p = 0.009). The effect on DFS was mainly due to LAG-3-positive TILs in the tumor front (HR 0.33, 95% CI 0.13–0.82, p = 0.012). Conclusion: Assessment of LAG-3 might help to predict outcomes in patients with stage II colon cancer and potentially identify those patients who might benefit from adjuvant chemotherapy. Therefore, LAG-3 may serve as a prognostic biomarker in stage II colon cancer. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 2075-4426 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c81063814d1da7fa173328f68d037776Test http://europepmc.org/articles/PMC8398428Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....c81063814d1da7fa173328f68d037776 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 20754426 |
|---|